You are an elite MBBS pharmacology professor, clinical pharmacologist, medical educator, pathophysiologist, and examination coach. Create a COMPLETE LEARNING NOTE for the topic(s) provided. The goal is NOT merely to summarize information. The goal is to teach the topic from absolute beginner level to MBBS examination mastery level. Assume the student has never seen the topic before. Write in extremely clear, plain English. Use language simple enough for a 9-year-old child to understand initially, then gradually build to MBBS level understanding. Never sacrifice understanding for brevity. Do not use unexplained jargon. Whenever a technical term is introduced: 1. Define it. 2. Explain why it matters. 3. Explain it using a simple analogy. 4. Explain it again in proper medical language. For every topic, use the following structure. --- SECTION 1: BIG PICTURE OVERVIEW Start with: "What problem does this drug class solve?" Explain: Why the disease occurs Why the microorganism survives What the drug is trying to achieve Where the drug acts Create a mental picture before discussing drugs. --- SECTION 2: BUILD THE FOUNDATION Before discussing drugs: Explain all background physiology. Explain all background microbiology. Explain all relevant pathology. Answer: What is normally happening? What goes wrong? Why does it go wrong? Where can drugs intervene? Use diagrams in text format where appropriate. Example: Bacterium ↓ Needs cell wall ↓ Cell wall keeps bacterium alive ↓ Drug blocks wall formation ↓ Wall becomes weak ↓ Bacterium dies --- SECTION 3: DRUG CLASS FRAMEWORK For each drug class explain: Definition Mechanism of action Why the mechanism works Spectrum of activity Important examples Clinical uses Adverse effects Contraindications Drug interactions Resistance mechanisms High-yield examination facts Common MCQs Most frequently tested concepts --- SECTION 4: TEACH USING ANALOGIES Create memorable analogies. Examples: Penicillin: "The bacterial cell wall is like a brick wall protecting a house. Penicillin prevents the workers from laying the bricks." Aminoglycosides: "The bacterial ribosome is like a factory producing products. Aminoglycosides force the factory to produce defective products." Sulfonamides: "Like cutting off a city's food supply." Always use vivid memorable analogies. --- SECTION 5: STEP-BY-STEP CLINICAL REASONING Teach how a doctor thinks. Example: Patient has pneumonia. Question 1: What organisms commonly cause it? Question 2: Which drugs cover those organisms? Question 3: Which drug reaches the lungs well? Question 4: What patient factors influence choice? Question 5: What adverse effects must be considered? Walk through reasoning systematically. --- SECTION 6: MEMORY TOOLS Create: Mnemonics Memory stories Visual memory tricks Drug comparison tables Rapid review boxes Focus only on useful mnemonics. --- SECTION 7: EXAMINER'S CORNER For each topic include: Most tested facts Most likely essay questions Most likely short notes Most likely viva questions Most likely MCQs Common traps students fall into How examiners phrase questions - SECTION 9: HIGH-YIELD REVISION SHEET End with: One-page revision summary Most important facts Must-know drugs Must-know toxicities Must-know mechanisms Must-know clinical uses Exam emergency facts --- SECTION 10: SELF-ASSESSMENT Create: 10 short-answer questions Provide answers with explanations. --- SPECIAL INSTRUCTIONS Do not assume prior knowledge. Teach before summarizing. Explain every mechanism step-by-step. Explain every adverse effect by linking it to physiology and pathophysiology. When discussing drugs, always answer: "What exactly is the drug doing?" "Why does that action help the patient?" "Why does that action produce the side effects?" "Why might resistance develop?" Use tables wherever helpful. Use comparison tables extensively. Make the note so comprehensive that an MBBS student can use it as their primary learning resource without needing another source for conceptual understanding. TOPICS TO COVER: Mania and ADHD

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Searching PubMed

lithium bipolar mania treatment

Searching PubMed

ADHD pharmacotherapy stimulants children

I now have comprehensive material from multiple authoritative sources. Let me write the complete learning note.

COMPLETE LEARNING NOTE: PHARMACOLOGY OF MANIA AND ADHD

From Zero to MBBS Examination Mastery

Sources: Stahl's Essential Psychopharmacology, Lippincott Illustrated Reviews Pharmacology, Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Katzung's Basic and Clinical Pharmacology 16e, Eric Kandel's Principles of Neural Science 6e

PART 1: MANIA - COMPLETE LEARNING NOTE

SECTION 1: BIG PICTURE OVERVIEW - MANIA

What problem does this drug class solve?

Imagine your brain has a "volume control" for mood, energy, and thoughts. In most people, this volume control works normally - it turns up when something exciting happens, and comes back down when things settle. In a person with mania, this volume control gets jammed at maximum and cannot come back down.

The person becomes:

Extremely "high" in mood (euphoric)
Full of boundless energy (no need for sleep)
Racing thoughts, talking very fast
Feeling they can do anything (grandiosity)
Making extremely poor decisions (spending all money, risky behaviour)
Sometimes hearing or seeing things (psychosis in severe mania)

This is not happiness. This is a medical emergency - the brain has lost its ability to regulate itself.

The drugs we use for mania are trying to "bring the volume control back down" - to stabilise the brain's mood regulation system.

These drugs are called mood stabilisers.

SECTION 2: BUILD THE FOUNDATION

2A. Normal Mood Regulation - What is normally happening?

Your brain controls mood through a system of chemical messengers called neurotransmitters (neuro = brain, transmitter = messenger). Think of these like WhatsApp messages sent between brain cells (neurons).

The three most important neurotransmitters in mood are:

Neurotransmitter	What it does when active	Where it mainly acts
Dopamine (DA)	Reward, motivation, pleasure, energy	Limbic system, prefrontal cortex
Serotonin (5-HT)	Mood regulation, calmness, sleep	Raphe nuclei → whole brain
Norepinephrine (NE)	Alertness, arousal, stress response	Locus coeruleus → whole brain

Normal mood = these three neurotransmitters are released in balanced amounts, and their signals are regulated carefully by:

Reuptake transporters - pumps that suck the messenger back into the sending cell after use
Autoreceptors - sensors on the sending cell that say "you've sent enough, stop"
Second messenger systems - the cell machinery that translates the message into action

2B. What goes wrong in Mania?

Think of a city with a traffic light system. Normally, traffic lights regulate the flow of cars (neurotransmitters). In mania, all the traffic lights are jammed green - everything rushes through at once with no control.

The exact cause of mania is still being studied, but we know:

Dopamine overdrive - Too much dopamine activity in the limbic system creates euphoria, grandiosity, and reward-seeking behaviour. This is like your brain's reward circuit firing non-stop.
Norepinephrine excess - Too much NE creates increased energy, decreased need for sleep, racing thoughts, and hyperarousal.
Serotonin dysregulation - Serotonin is not regulating mood properly, allowing the other systems to run unchecked.
Disrupted second messenger signalling - The internal machinery of brain cells goes haywire. Specifically:
- The phosphatidylinositol (PI) cycle becomes overactive
- G proteins (which relay signals inside cells) are dysregulated
- GSK-3 (Glycogen Synthase Kinase-3) - an enzyme that helps regulate gene expression in brain cells - becomes overactive, leading to unstable neuronal function

This is why mania is not just "feeling happy" - the brain's internal regulatory machinery has broken down.

2C. The Bipolar Disorder Framework

Bipolar disorder (formerly called manic-depressive illness) is the condition in which people swing between:

Mania (the "up" phase) - the brain is in overdrive
Depression (the "down" phase) - the brain is in underdrive
Euthymia (normal mood) - the goal of treatment

Mania (brain overdrive)
        ↑        ↓
  EUTHYMIA (normal)       ← GOAL of mood stabilisers
        ↓        ↑
Depression (brain underdrive)

Types of Bipolar Disorder:

Bipolar I - Full manic episodes (can be psychotic), usually with depressive episodes
Bipolar II - Hypomania (milder, shorter mania) + depressive episodes
Cyclothymia - Milder swings over 2+ years

2D. Where Can Drugs Intervene?

Neurotransmitter excess (DA, NE)
            ↓
Activates receptors on brain cells
            ↓
Triggers G protein signalling cascades
            ↓
Second messengers (cAMP, IP3, DAG) activated
            ↓
Activates kinases (GSK-3, PKC)
            ↓
Alters gene expression and neuronal excitability
            ↓
MANIA symptoms

← LITHIUM blocks here (inositol, G proteins, GSK-3)
← VALPROATE blocks here (GABA↑, sodium channels)
← CARBAMAZEPINE blocks here (sodium channels)
← ANTIPSYCHOTICS block at dopamine receptors (top)

SECTION 3: DRUG CLASS FRAMEWORK - MANIA

DRUG CLASS 1: LITHIUM

What is Lithium?

Lithium is the simplest drug in psychiatry. It is a metal ion - just like sodium (Na⁺) and potassium (K⁺) that you already know. Its chemical symbol is Li⁺. It is the lightest metal on the periodic table.

Lithium is given as lithium carbonate (Li₂CO₃) tablets.

It was discovered to treat mania by Australian psychiatrist John Cade in 1949 - making it one of the oldest psychiatric medications still in use today.

Mechanism of Action

Lithium's exact mechanism is not fully understood, but multiple mechanisms are proposed (Stahl's Essential Psychopharmacology):

Mechanism 1 - Inositol Depletion (Phosphatidylinositol Cycle)

Inside neurons, there is a messaging system that uses a molecule called inositol. Think of inositol like a rechargeable battery that powers the messaging system inside the cell.

Here is the normal cycle:

PI (phosphatidylinositol) in cell membrane
            ↓ (receptor activated)
PI is broken into IP3 + DAG (these are the "messages" inside the cell)
            ↓
IP3 and DAG carry out cellular effects (contribute to mania)
            ↓
IP3 is broken down to inositol monophosphate (IMP)
            ↓
IMP is converted back to free inositol by the enzyme INOSITOL MONOPHOSPHATASE
            ↓
Free inositol is recycled back into PI (battery recharged)

Lithium BLOCKS the enzyme inositol monophosphatase. This means:

IMP cannot be converted back to free inositol
The "battery" cannot be recharged
The PI signalling cycle runs out of fuel
Overactive neurons (which were driving mania) quieten down

This is called the "inositol depletion hypothesis" of lithium's action.

Mechanism 2 - GSK-3 Inhibition

Lithium inhibits Glycogen Synthase Kinase-3 (GSK-3) - an enzyme deep inside the cell that controls gene expression and neuronal plasticity. By inhibiting GSK-3, lithium may:

Reduce neuronal excitability
Promote neuroprotection (actually protect brain cells)
Regulate neurotrophic factors (growth factors for brain cells)

Mechanism 3 - G Protein Modulation

Lithium modulates G proteins - the relay stations inside neurons that carry signals from surface receptors to internal machinery. By uncoupling overactive G protein signalling, lithium reduces the downstream cascade that leads to mania.

Why Do These Mechanisms Help?

Together, lithium acts like a "master switch" that:

Depletes the fuel (inositol) that overactive neurons need
Turns off the enzyme (GSK-3) that keeps neurons firing abnormally
Uncouples the relay stations (G proteins) that amplify signals

The result: overactive manic neurons calm down.

Therapeutic Uses of Lithium

Use	Details
Acute mania	First-line for euphoric mania
Bipolar maintenance	Reduces frequency and severity of both manic and depressive episodes
Bipolar depression	Can be used (less effective than for mania)
Augmentation for depression	Added to antidepressants in treatment-resistant unipolar depression
Anti-suicide effect	Lithium is the ONLY mood stabiliser with proven anti-suicide effects
Cluster headache prophylaxis	Less common use

Pharmacokinetics (How Lithium Moves Through the Body)

Absorption: Readily absorbed orally (nearly 100% bioavailability)

Distribution: Distributes throughout body water. Does NOT bind to plasma proteins (this is high-yield - unlike most drugs, it has 0% protein binding).

The "sodium mimicry" problem: Li⁺ behaves like Na⁺ in the body because they are both small cations (positively charged ions). The kidney cannot tell them apart properly. This creates a major pharmacokinetic challenge:

When the body is dehydrated or sodium-depleted (e.g., diarrhoea, diuretics, low-salt diet, sweating), the kidney retains lithium thinking it is sodium → lithium levels rise → TOXICITY
This is the most important pharmacokinetic fact about lithium

Excretion: Entirely by the kidneys (renal excretion). Half-life = 18-36 hours.

Therapeutic window: 0.6-1.2 mEq/L (for maintenance); 0.8-1.2 mEq/L (for acute mania)

Note: This is a narrow therapeutic window - the gap between a working dose and a toxic dose is small.

Adverse Effects of Lithium

Lithium has many adverse effects. Understanding WHY each occurs makes them easier to remember.

1. Gastrointestinal Effects (Very Common)

Nausea, vomiting, diarrhoea, dyspepsia
Why: Lithium irritates the GI mucosa and also affects smooth muscle
When: Usually early in treatment or with high levels
Trick: Giving lithium with food reduces GI side effects

2. Tremor (Fine hand tremor)

Why: Lithium interferes with sodium-potassium ATPase in neurons, causing slight neuronal instability
Fine postural tremor - worse when hands are held outstretched
Management: Beta-blockers (propranolol)

3. Polyuria and Polydipsia (Nephrogenic Diabetes Insipidus - NDI)

Why: Lithium blocks the action of ADH (Antidiuretic Hormone) on the collecting duct of the kidney. Normally ADH tells the kidney to reabsorb water. When lithium blocks this, the kidney loses water → patient passes large amounts of dilute urine → gets thirsty → drinks a lot
This is called nephrogenic diabetes insipidus (nephrogenic = kidney-caused; diabetes insipidus = passing large amounts of tasteless/dilute urine)
Not the same as diabetes mellitus - no sugar involved
Management: Amiloride (potassium-sparing diuretic) can help

4. Hypothyroidism

Why: Lithium blocks thyroid hormone synthesis and release. It inhibits iodine uptake by the thyroid gland and inhibits thyroid hormone secretion
Can cause a goitre (thyroid enlargement as the gland tries to compensate)
Management: Check thyroid function tests (TFTs) every 6 months; replace with thyroxine if needed

5. Weight Gain

Common and often distressing for patients
Mechanism: increased appetite, fluid retention, hypothyroidism

6. Cognitive Effects

Memory impairment, slowed thinking, difficulty concentrating
Often described by patients as feeling "foggy"

7. Acne and Psoriasis exacerbation

Lithium can worsen skin conditions

8. Hair Loss (Alopecia)

Relatively common

9. ECG Changes

T-wave flattening or inversion (usually benign)
Sinus node dysfunction in some patients

10. Renal Toxicity (Long-term)

Chronic lithium use can cause tubular damage and, in severe cases, chronic kidney disease (CKD)
Why: Lithium is directly nephrotoxic (toxic to kidney tubular cells) with long-term use
Regular monitoring of renal function (urea, creatinine, eGFR) is mandatory

LITHIUM TOXICITY - Critical High-Yield Section

Lithium toxicity is a medical emergency because the therapeutic window is so narrow.

Causes of Toxicity:

Dehydration (any cause - sweating, diarrhoea, vomiting)
Low-salt diet
NSAIDs (ibuprofen, diclofenac) - reduce renal blood flow → reduce lithium excretion → lithium accumulates
Thiazide diuretics - increase sodium excretion → kidney retains lithium to compensate
ACE inhibitors - reduce renal perfusion
Renal failure
Intentional overdose

Lithium Toxicity Levels and Features:

Serum Level (mEq/L)	Features
1.5-2.0	Mild: nausea, vomiting, diarrhoea, tremor, drowsiness
2.0-2.5	Moderate: confusion, agitation, coarse tremor, ataxia (poor coordination), dysarthria (slurred speech), muscle twitching
>2.5	Severe: seizures, coma, cardiac arrhythmias, permanent neurological damage, death

The DIT Triad of severe lithium toxicity:

D - Drowsiness / Disorientation
I - Incoordination
T - Tremor (coarse)

Management of Lithium Toxicity:

STOP lithium immediately
IV fluid hydration (sodium-containing fluids to help kidney excrete lithium)
Haemodialysis for severe toxicity (Li⁺ >3.0 mEq/L or neurological symptoms)
No specific antidote exists

Monitoring Requirements for Lithium

Before starting and during lithium therapy:

Test	Frequency	Why
Serum lithium level	Initially weekly until stable, then every 3-6 months	Narrow therapeutic window
Renal function (eGFR, creatinine)	Every 6 months	Nephrotoxicity
Thyroid function (TSH, T4)	Every 6 months	Hypothyroidism
ECG	Baseline	Cardiac effects
Full blood count	Baseline	Leukocytosis is common with lithium (benign)
Pregnancy test	Before starting in women of reproductive age	Teratogenicity

Lithium in Pregnancy - IMPORTANT

Ebstein's anomaly - a rare cardiac malformation (downward displacement of the tricuspid valve) is associated with first-trimester lithium exposure. The risk is real but smaller than initially reported.
Lithium is Category D in pregnancy (evidence of fetal risk)
If lithium must be used, close monitoring is required
Risk-benefit discussion is essential

Drug Interactions with Lithium

Drug	Effect on Lithium	Mechanism
NSAIDs	↑ Lithium levels (TOXICITY)	Reduce renal prostaglandin synthesis → ↓ renal lithium clearance
Thiazide diuretics	↑ Lithium levels (TOXICITY)	Na⁺ depletion → kidney retains Li⁺
ACE inhibitors / ARBs	↑ Lithium levels (TOXICITY)	↓ Renal blood flow → ↓ lithium excretion
Sodium-containing foods	High salt → ↓ lithium levels	Kidney excretes Na⁺ and Li⁺ together
Caffeine	↓ Lithium levels	Increases renal lithium clearance
Antipsychotics (typical)	Risk of neurotoxicity	Synergistic CNS effects
Loop diuretics (furosemide)	Less effect than thiazides but still monitor	Modest sodium/lithium interaction

Key rule: Anything that depletes sodium will increase lithium (because the kidney tries to retain more sodium - and takes up lithium along with it).

DRUG CLASS 2: VALPROATE (VALPROIC ACID / SODIUM VALPROATE)

What is Valproate?

Valproate is an anticonvulsant (anti-seizure drug) that also works as a mood stabiliser. This seems surprising, but mania and seizures actually share some neurological mechanisms.

Valproate is available as:

Valproic acid (VPA)
Sodium valproate (more commonly used)
Valproate semisodium (Depakote) - extended release

Mechanism of Action of Valproate

Valproate works through multiple mechanisms (it is a "dirty drug" - meaning it has many targets, which is actually useful in complex diseases like mania):

1. Sodium Channel Blockade

Valproate blocks voltage-gated sodium channels in neurons
It specifically blocks channels in the inactivated state (meaning it stabilises channels after they have fired and prevents them from firing again too quickly)
This reduces the rate of neuronal firing - overactive neurons slow down
Analogy: Imagine a machine gun that fires very rapidly. Valproate puts a clip on the trigger that prevents it from firing again too fast after each shot.

2. GABA Enhancement

GABA (gamma-aminobutyric acid) is the brain's main "braking" neurotransmitter - it tells neurons to STOP firing
Valproate increases GABA levels by:
- Inhibiting the enzyme GABA transaminase (which breaks down GABA)
- Increasing GABA synthesis
- Increasing GABA-A receptor sensitivity
The result: more braking signal → overactive manic neurons are quietened

3. Calcium Channel Blockade (T-type)

Blocks T-type calcium channels (also involved in neuronal excitability)

4. GSK-3 Inhibition (similar to lithium)

Spectrum of Use

Indication	Notes
Acute mania	First-line (especially for mixed episodes, rapid cycling)
Bipolar maintenance	Especially better than lithium for mixed states and rapid cycling
Epilepsy	Broad-spectrum anticonvulsant
Migraine prophylaxis	Reduces frequency of migraines
NOT indicated for bipolar depression	Evidence lacking

Valproate is preferred over lithium when:

Mixed episodes (mania + depression simultaneously)
Rapid cycling (4+ episodes per year)
Dysphoric mania (mania with irritability rather than euphoria)
Substance abuse comorbidity

Adverse Effects of Valproate

1. Gastrointestinal - Nausea, vomiting, indigestion (improve with enteric-coated formulation)

2. Weight Gain - Very common and significant

3. Tremor - Fine tremor similar to lithium

4. Hair Loss (Alopecia) - Diffuse hair thinning; zinc and selenium supplements may help

5. Hepatotoxicity (MOST DANGEROUS)

Fatal hepatic failure can occur, especially in children under 2 years
The mechanism: Valproate is converted to a toxic metabolite 4-ene-VPA which damages mitochondria in liver cells
Monitor LFTs (liver function tests)
Highest risk: Children under 2, patients on multiple anticonvulsants, patients with metabolic disorders

6. Pancreatitis - Rare but potentially fatal; presents with abdominal pain + raised amylase/lipase

7. Thrombocytopenia - Low platelet count → bleeding risk

8. Hyperammonaemia - Elevated blood ammonia → confusion, even without liver disease

9. TERATOGENICITY - Most Important Contraindication

Valproate is highly teratogenic:

Neural tube defects (spina bifida, anencephaly) - 2-5x increased risk vs normal population
Valproate syndrome: Facial dysmorphism, cleft palate, limb defects
Neurodevelopmental harm: Children exposed in utero have reduced IQ, autism spectrum disorders, cognitive delays - this effect is irreversible
This is why valproate is ABSOLUTELY CONTRAINDICATED in pregnancy and in women of reproductive age without highly effective contraception

Drug Interactions of Valproate

Drug	Effect
Lamotrigine	Valproate doubles lamotrigine levels (inhibits its glucuronidation) → risk of Stevens-Johnson Syndrome
Carbamazepine	Carbamazepine induces valproate metabolism → ↓ valproate levels
Aspirin	Displaces valproate from protein binding → ↑ free valproate
Warfarin	Valproate displaces warfarin → ↑ anticoagulation
Phenytoin	Complex interaction - monitor both levels

DRUG CLASS 3: CARBAMAZEPINE

What is Carbamazepine?

Carbamazepine (CBZ) is another anticonvulsant used as a mood stabiliser, especially for bipolar disorder when lithium fails.

Brand names: Tegretol, Mazetol

Mechanism of Action

Primary mechanism: Blocks voltage-gated sodium channels in the inactivated state (similar to valproate but more selective for this mechanism)

Stabilises neuronal membranes by preventing repetitive firing
Also has some effects on calcium channels

Therapeutic Uses

Use	Notes
Acute mania	Especially when lithium has failed
Bipolar maintenance	Alternative to lithium
Trigeminal neuralgia	First-line drug for this condition
Epilepsy	Partial seizures, tonic-clonic
Neuropathic pain	Various types

Adverse Effects of Carbamazepine

1. CNS Effects - Diplopia (double vision), dizziness, ataxia, sedation, blurred vision (very common, especially at start)

2. Hyponatraemia (Low Sodium) - Carbamazepine has ADH-like effects (SIADH) → kidney retains water → blood sodium diluted → hyponatraemia

3. Haematological (Most Dangerous):

Aplastic anaemia - failure of bone marrow to produce blood cells - rare but can be fatal
Agranulocytosis - loss of white blood cells → severe infections
Requires monitoring of full blood count

4. Hepatotoxicity - Elevated liver enzymes; rarely fatal hepatitis

5. Skin Reactions:

Maculopapular rash (common)
Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN) - rare but life-threatening skin reactions
HLA-B*1502 allele (found in Han Chinese and other Asian populations) dramatically increases risk of SJS - genetic testing recommended before use in these populations

6. Teratogenicity:

Neural tube defects (but less than valproate)
Fetal carbamazepine syndrome: fingernail hypoplasia, facial dysmorphism
Folate supplementation recommended

7. Enzyme Induction (Very Important Pharmacokinetically):

Carbamazepine is a potent inducer of CYP3A4, CYP2C9, CYP1A2
It also induces its own metabolism = autoinduction (over weeks of treatment, it metabolises itself faster, requiring dose increases)
This means it reduces levels of many other drugs: oral contraceptives (OCP), warfarin, other anticonvulsants, HIV protease inhibitors
Patients on OCP MUST use alternative contraception

DRUG CLASS 4: LAMOTRIGINE

What is Lamotrigine?

Lamotrigine (LTG) is an anticonvulsant that is uniquely "depression-minded" among mood stabilisers (Stahl's Essential Psychopharmacology). Unlike lithium, valproate, and carbamazepine which primarily treat mania, lamotrigine primarily treats the depressive episodes of bipolar disorder.

Mechanism of Action

Blocks voltage-gated sodium channels (similar to carbamazepine)
Also blocks calcium channels
Reduces release of glutamate (the main excitatory neurotransmitter) by stabilising the presynaptic membrane

Clinical Uses

Bipolar depression - First-line for depressive episodes in bipolar II
Bipolar maintenance - Reduces relapse into depression
Epilepsy - Partial and generalised seizures
NOT effective for acute mania - This is a critical fact; do not confuse with lithium/valproate

Major Adverse Effect: Stevens-Johnson Syndrome (SJS)

SJS is the most feared adverse effect of lamotrigine
It is a severe skin reaction where the skin blisters and peels off (like being burned)
It can be fatal
Risk is dramatically increased if lamotrigine is started at a high dose or escalated too quickly
Valproate doubles lamotrigine levels - if used together, lamotrigine dose must be halved and titrated very slowly

Rule: Lamotrigine must ALWAYS be started at a very low dose and increased very slowly (over weeks). This is called the "go slow" approach.

Other adverse effects: headache, dizziness, diplopia, nausea, insomnia

Memory trick: "LAMO = LAst resort for Mania, but gOod for depression"

DRUG CLASS 5: ANTIPSYCHOTICS IN MANIA

Why use antipsychotics for mania?

Dopamine overdrive is a core feature of mania. Since antipsychotics block dopamine D2 receptors, they directly address one of the key mechanisms.

Typical antipsychotics (first generation) like haloperidol can control acute mania rapidly, especially when there is psychosis (delusions, hallucinations).

Atypical antipsychotics (second generation) are now preferred because they block both D2 (dopamine) and 5-HT2A (serotonin) receptors:

Olanzapine - FDA approved for acute mania and bipolar maintenance
Quetiapine - FDA approved for acute mania AND bipolar depression
Risperidone - for acute mania
Aripiprazole - FDA approved for bipolar I maintenance
Asenapine - FDA approved for mixed episodes

Why use atypicals over lithium/valproate in acute mania?

They work faster (within hours vs days-weeks for lithium)
They directly control psychotic features
Often used in combination with mood stabilisers

SECTION 4: ANALOGIES FOR MANIA

Lithium - "The Master Thermostat Fixer"

Imagine your house has a central heating thermostat that is stuck at maximum - the house is burning hot and you cannot turn it down. All the individual radiators are working too hard.

Lithium does not go to each individual radiator (neurotransmitter receptor) to turn it down. Instead, it goes to the boiler control room (the second messenger system) and fixes the thermostat itself. The fuel supply (inositol) is cut, the main control panel (GSK-3) is reset, and gradually the entire heating system settles back to normal.

This is why lithium is uniquely effective - it acts at a fundamental level, not at the surface.

Valproate - "The Brake Booster AND the Speed Limiter"

Your car (the neuron) is going too fast. Valproate:

Boosts the brakes (increases GABA, the brain's braking system)
Puts on a speed limiter (blocks sodium channels so the neuron cannot fire too rapidly)
Reduces fuel intake (reduces glutamate release)

Three mechanisms, one drug, one goal - slow the overactive neuron down.

Carbamazepine - "The Circuit Breaker"

Imagine electrical circuits in a building (neurons in the brain) that keep short-circuiting and tripping the whole system. A circuit breaker prevents electricity from flowing when the circuit overloads.

Carbamazepine acts like a circuit breaker on the sodium channel - when a neuron fires too many times, carbamazepine blocks the sodium channel and prevents it from firing again immediately.

Antipsychotics - "Blocking the Loudspeaker"

The dopamine system in mania is like a loudspeaker turned to maximum volume. Antipsychotics grab the speaker cable (block the D2 receptor) and immediately reduce the volume. They are fast-acting but do not fix the underlying amplifier problem.

SECTION 5: CLINICAL REASONING - MANIA

Case: Mr. K, 28 years old

Presentation: Mr. K has not slept for 3 days. He believes he has invented a perpetual motion machine, has spent his entire savings, is talking at high speed, and cannot be interrupted. He has a history of one previous depressive episode 2 years ago. His father has bipolar disorder.

Step 1: What is the diagnosis? Bipolar I disorder - first manic episode

Evidence: decreased need for sleep, grandiosity, rapid speech (pressured speech), impulsive behaviour
Family history supports genetic risk

Step 2: Is there psychosis? Grandiosity with a fixed false belief (perpetual motion machine) - may be a grandiose delusion (psychotic feature) If yes: antipsychotic is urgently needed alongside mood stabiliser

Step 3: What does acute management look like?

ACUTE PHASE (days to weeks):
├── Option A: Lithium + Haloperidol (or atypical antipsychotic)
├── Option B: Valproate + Antipsychotic
└── Option C: Antipsychotic monotherapy (olanzapine, aripiprazole)

Goal: Rapid control of symptoms

Step 4: Why choose one over another?

Factor	Choice
Euphoric mania, no psychosis	Lithium first
Mixed episode (mania + depression)	Valproate preferred
Rapid cycling (4+ episodes/year)	Valproate preferred
Psychotic features	Add antipsychotic immediately
Cannot tolerate lithium's side effects	Switch to valproate or atypical antipsychotic
Pregnancy risk (female of reproductive age)	AVOID valproate; lithium with caution; prefer quetiapine or lamotrigine

Step 5: Maintenance (long-term prevention)

MAINTENANCE PHASE (months to years):
├── Lithium (reduces mania AND depression; proven anti-suicide effect)
├── Valproate (especially for mania-predominant bipolar I)
├── Lamotrigine (especially for depression-predominant or bipolar II)
└── Atypical antipsychotics (quetiapine, aripiprazole, olanzapine)

Step 6: What must be monitored?

Lithium: levels, TFTs, renal function
Valproate: LFTs, FBC, pregnancy test
Carbamazepine: FBC, LFTs, sodium levels, drug interactions

SECTION 6: MEMORY TOOLS - MANIA

Mnemonic for Lithium Side Effects: "LITHIUM"

L - Low thyroid (hypothyroidism)
I - Inositol depleted (mechanism)
T - Tremor (fine)
H - Hyperparathyroidism / Hair loss
I - Increased urination (nephrogenic DI) / Increased thirst
U - Urea rises (nephrotoxicity long-term)
M - Memory problems / nausea / metallic taste

Mnemonic for drugs that INCREASE lithium levels (toxicity risk): "ANTI"

A - ACE inhibitors (and ARBs)
N - NSAIDs
T - Thiazide diuretics
I - Infections with dehydration/fever

Mnemonic: Valproate teratogenicity = "VALVE"

V - Valproate
A - Always teratogenic
L - Low IQ in offspring
V - aNd facial defects
E - Especially neural tube defects

Mood Stabiliser Comparison Table

Drug	Acute Mania	Bipolar Depression	Maintenance	Main Concern
Lithium	✓✓	✓	✓✓✓	Narrow window, toxicity
Valproate	✓✓✓	✗	✓✓	Teratogenicity
Carbamazepine	✓✓	✗	✓✓	Aplastic anaemia, CYP induction
Lamotrigine	✗	✓✓✓	✓✓✓	SJS, must titrate slowly
Quetiapine	✓✓✓	✓✓✓	✓✓	Metabolic syndrome
Olanzapine	✓✓✓	✓	✓✓	Weight gain, metabolic
Aripiprazole	✓✓	✗	✓✓	Akathisia

PART 2: ADHD - COMPLETE LEARNING NOTE

SECTION 1: BIG PICTURE OVERVIEW - ADHD

What problem does this drug class solve?

Imagine a classroom where most children can sit still, pay attention to the teacher, wait their turn, and organise their thoughts. Now imagine one child who:

Cannot sit still for more than 30 seconds
Starts ten activities and finishes none
Blurts out answers without raising their hand
Loses their pencil case every day
Knows they should focus but simply cannot, no matter how hard they try

This child does not have a bad attitude. Their brain is wired differently. The parts of the brain responsible for attention, impulse control, and organisation are not working with enough chemical signal.

The drugs for ADHD solve this by delivering more dopamine and norepinephrine signal to the very brain circuits that need it - specifically the prefrontal cortex (the brain's "executive function" centre).

SECTION 2: BUILD THE FOUNDATION - ADHD

2A. What is Normal Attention? The Prefrontal Cortex (PFC)

The prefrontal cortex (PFC) is the part of the brain that sits just behind your forehead. It is the brain's "executive" - like the CEO of the brain. It is responsible for:

Sustained attention - maintaining focus on one task
Working memory - holding information in mind temporarily ("mental notepad")
Impulse control - stopping yourself from doing things impulsively
Organisation and planning - breaking big tasks into steps
Emotion regulation - managing feelings appropriately

The PFC performs these functions by:

Generating signals - neurons in the PFC communicate using dopamine (DA) and norepinephrine (NE)
Maintaining a steady, appropriate level of chemical signal - not too much, not too little

The PFC operates on a "Goldilocks principle": Too little DA/NE signal = poor attention (ADHD). Too much = anxiety, inability to filter thoughts. Just right = optimal focus and executive function.

2B. What Goes Wrong in ADHD?

In ADHD, there is insufficient dopamine and norepinephrine signalling in the prefrontal cortex and related circuits.

Why does this happen? Multiple mechanisms:

Genetic variants in dopamine transporter genes (DAT1), dopamine receptor genes (DRD4, DRD5), and norepinephrine genes
These variants cause overly efficient reuptake - dopamine and norepinephrine are sucked back into the sending neuron too quickly, before they can fully stimulate the receiving neuron
Result: the PFC's "signal strength" is chronically low

Normal:
Neuron fires → DA/NE released → Acts on receptors for appropriate time → Reuptake occurs → Normal signalling

ADHD:
Neuron fires → DA/NE released → RAPID REUPTAKE (transporter too active) → Signal too short/weak → Poor PFC function

2C. The Neurobiology of ADHD in More Detail

Dopamine pathways relevant to ADHD:

Mesocortical pathway: Midbrain (VTA) → Prefrontal cortex - governs executive functions, attention
Mesolimbic pathway: Midbrain (VTA) → Limbic system (nucleus accumbens) - governs reward, motivation
In ADHD, both are underactive

Norepinephrine pathways relevant to ADHD:

Locus coeruleus → Prefrontal cortex - NE from the locus coeruleus (LC) acts on α2A adrenoceptors in the PFC to maintain sustained attention and working memory
In ADHD, this NE signal is too weak

2D. ADHD Diagnostic Criteria (DSM-5) - Brief Overview

ADHD has three presentations:

Predominantly Inattentive - mainly concentration/memory problems
Predominantly Hyperactive-Impulsive - mainly hyperactivity and impulsivity
Combined presentation - most common in children

Core symptom domains:

INATTENTION SYMPTOMS:          HYPERACTIVITY/IMPULSIVITY:
• Poor sustained attention      • Fidgets, can't sit still
• Easily distracted            • Runs/climbs inappropriately
• Forgetful                    • Can't play quietly
• Doesn't follow through        • Always "on the go"
• Loses things                 • Talks excessively
• Poor organisation            • Blurts out answers
• Avoids sustained tasks       • Can't wait their turn

Symptoms must be present before age 12, in 2+ settings (school + home), and cause significant impairment.

2E. Where Can Drugs Intervene?

Insufficient DA/NE in PFC
            ↓
Poor attention, impulse control, hyperactivity
            ↓

← STIMULANTS block here:
   Methylphenidate: blocks DAT and NET (reuptake transporters)
   Amphetamine: blocks AND reverses DAT and NET (forces release)

← NON-STIMULANTS block here:
   Atomoxetine/Viloxazine: selectively block NET (NE reuptake)
   Guanfacine/Clonidine: stimulate α2A receptors directly

SECTION 3: DRUG CLASS FRAMEWORK - ADHD

ADHD DRUG CLASS 1: STIMULANTS

Why are "stimulants" used for a child who is already hyperactive?

This seems paradoxical. The answer is: stimulants increase dopamine and norepinephrine specifically in the PFC, where they activate the brain's braking and self-regulation system.

It is like using electricity to power a circuit breaker. You add more signal, but the signal activates the brain areas that CONTROL hyperactivity and impulsivity.

In ADHD, stimulants have a paradoxical calming effect precisely because the PFC was under-stimulated.

STIMULANT A: METHYLPHENIDATE

Brand names: Ritalin (immediate-release), Concerta (extended-release), Daytrana (patch)

Chemical nature: Piperidine derivative (structurally distinct from amphetamine but similar pharmacology)

Available forms:

Methylphenidate (racemic = D+L mixture)
Dexmethylphenidate = D-isomer only (Focalin) - more potent, fewer side effects
Serdexmethylphenidate - prodrug of dexmethylphenidate

Mechanism of Action of Methylphenidate (Stahl's + Lippincott)

Step-by-step:

1. Methylphenidate enters the brain (crosses blood-brain barrier easily)

2. It binds to the DOPAMINE TRANSPORTER (DAT) - NOT at the dopamine-binding site but at an ALLOSTERIC site (a different location on the transporter)

3. This BLOCKS the DAT (the pump that normally removes dopamine from the synapse)

4. Dopamine cannot be pumped back into the neuron → stays in the synapse longer

5. More sustained dopamine stimulation of post-synaptic receptors in PFC

6. Similarly blocks the NOREPINEPHRINE TRANSPORTER (NET) - less potently
   → More norepinephrine in the synapse

7. Both DA and NE are now present in higher concentrations and for longer

8. The PFC neurons receive better signal → improved attention, impulse control, working memory

Key distinction: Methylphenidate blocks the transporter (like putting a stopper in a drain) - it does NOT release dopamine by itself.

D vs L isomers (Stahl's):

D-methylphenidate (dexmethylphenidate) has greater potency for both DAT and NET than L-methylphenidate
This is why dexmethylphenidate (Focalin) requires a lower dose

Pharmacokinetics of Methylphenidate

Property	Details
Absorption	Rapid oral absorption
Peak effect	1-2 hours (immediate release), 6-8 hours (extended release)
Duration (immediate release)	3-5 hours
Metabolism	Hepatic, de-esterified to ritalinic acid (inactive)
Excretion	Urine (as ritalinic acid)
Food effect	Food slightly delays but doesn't reduce absorption

Formulation strategy matters:

Immediate-release: given 2-3 times daily (school morning, afternoon doses)
Extended-release (Concerta): once daily in morning (lasts all school day)
Patch (Daytrana): applied to hip, provides sustained release

Adverse Effects of Methylphenidate

Adverse Effect	Mechanism	Notes
Decreased appetite / Anorexia	DA in hypothalamus suppresses hunger signals	Most common; give with meals; may affect growth in children
Insomnia	CNS stimulation → delayed sleep onset	Take earlier in the day; avoid evening doses
Headache	Vasoconstriction (mild)	Usually mild
Abdominal pain / Nausea	GI irritation	Give with food
Increased heart rate and blood pressure	NE effect on cardiovascular system	Monitor vitals; caution in cardiac disease
Growth suppression (in children)	Appetite suppression → poor nutrition	"Drug holidays" (off medication on weekends) may help; long-term effects debated
Tics	Increased dopamine can worsen motor tics	Use with caution in Tourette syndrome
Mood changes / Rebound	As drug wears off, DA drops below baseline transiently	Irritability, "rebound effect" in late afternoon
Seizures	Methylphenidate may INCREASE seizure frequency in patients with epilepsy	Use with caution in epilepsy
Cardiovascular risk	Sudden cardiac death reported in patients with underlying unrecognised cardiac abnormalities	Screen with ECG and family history before starting

Abuse potential: Both methylphenidate and amphetamines are Schedule II controlled substances (US) / Class B controlled substances (UK) because of high abuse potential.

STIMULANT B: AMPHETAMINE (AND DEXTROAMPHETAMINE, LISDEXAMFETAMINE)

Brand names: Adderall (mixed amphetamine salts), Vyvanse (lisdexamfetamine), Dexedrine (dextroamphetamine)

Available as:

Mixed amphetamine salts (75% dextroamphetamine, 25% levoamphetamine) = Adderall
Dextroamphetamine (pure D-isomer) = Dexedrine
Lisdexamfetamine = prodrug (see below)

Mechanism of Action of Amphetamine (Stahl's Detailed Account)

Amphetamine is more powerful than methylphenidate and works by multiple mechanisms:

At clinical (therapeutic) ADHD doses:

Step 1: Amphetamine enters the neuron (it acts as a "hitch-hiker" on the DAT/NET - rides the transporter INTO the neuron)

Step 2: Inside the neuron, it competitively inhibits VMAT (Vesicular Monoamine Transporter) - the pump that packages DA into storage vesicles

Step 3: DA leaks out of vesicles into the cytoplasm of the neuron

Step 4: Reverse transport occurs - DAT runs BACKWARDS, pumping cytoplasmic DA OUT into the synapse (the flood)

Step 5: Simultaneously, amphetamine also blocks reuptake (competitive inhibitor at DAT/NET)

RESULT: Massive increase in synaptic DA and NE

The difference between methylphenidate and amphetamine:

Methylphenidate = BLOCKS the drain (reuptake pump) → lets pool fill slowly
Amphetamine = BLOCKS the drain + FLOODS from within → much more rapid, powerful increase

At HIGH (abuse) doses:

Amphetamine additionally depletes DA vesicles, releases DA massively → euphoria, addiction, psychosis
This is NOT the therapeutic mechanism in ADHD
This is why amphetamine abuse differs qualitatively from therapeutic use

Lisdexamfetamine - A Special Prodrug

Lisdexamfetamine (Vyvanse) = L-lysine + dextroamphetamine, chemically bonded

When swallowed, enzymatic cleavage in the gut/blood releases dextroamphetamine
The prodrug form means:
1. Slower conversion → smoother, more gradual onset → less "rush"
2. Cannot be easily abused by injection or snorting (prodrug is inactive until hydrolysed)
3. Longer duration of action (10-14 hours)

Comparison: Methylphenidate vs Amphetamine

Feature	Methylphenidate	Amphetamine
Primary mechanism	DAT/NET blocker (allosteric)	DAT/NET blocker + reverser + VMAT inhibitor
Relative potency	Less potent	More potent
Dopamine increase	Blocks reuptake only	Blocks reuptake + reverses + releases
Duration (immediate release)	3-5 hours	4-6 hours
Abuse potential	High (Schedule II)	High (Schedule II)
Peripheral effects	Mild	More pronounced
Side effect profile	Milder	More pronounced

ADHD DRUG CLASS 2: NON-STIMULANT MEDICATIONS

Why use non-stimulants?

Stimulants fail or are not tolerated
Patient has substance abuse history (stimulants would be risky)
Comorbid tic disorder or Tourette syndrome
Comorbid anxiety (stimulants can worsen anxiety)
Parental refusal of stimulants

NON-STIMULANT A: ATOMOXETINE

Brand name: Strattera

Drug class: Selective Norepinephrine Reuptake Inhibitor (SNRI/NRI) - specifically for NE

Mechanism of Action of Atomoxetine

Atomoxetine → selectively blocks NET (Norepinephrine Transporter)
↓
More NE in the synapse (in PFC and other regions)
↓
Better stimulation of α2A adrenoceptors in PFC
↓
Improved attention and impulse control

ALSO: In PFC specifically, DAT expression is low.
Instead, NE transporters (NETs) clear BOTH NE AND DA in the PFC.
So blocking NET in PFC → more DA too → additional benefit

This is why atomoxetine works despite being a "norepinephrine only" drug - in the PFC, the NET is responsible for clearing both NE and DA. Block the NET → both go up in the PFC.

Key difference from stimulants: Atomoxetine does NOT block DAT in the limbic system (nucleus accumbens) - so it does NOT increase dopamine in the reward centre - meaning NO abuse potential, NOT a controlled substance.

Clinical Features of Atomoxetine

Feature	Details
Onset of action	SLOW - takes 2-6 weeks to see full effect (unlike stimulants which work within 1 hour)
Duration	Once daily dosing
Not a controlled substance	No abuse potential
Approved for	ADHD in children (6+), adolescents, and adults

Adverse Effects of Atomoxetine

Adverse Effect	Notes
Decreased appetite	Less severe than stimulants
GI upset (nausea, vomiting)	Take with food
Somnolence (sleepiness)	Usually transient
Increased heart rate and BP	Monitor cardiovascular status
Urinary retention	NE → increases urethral tone; caution in BPH
Hepatotoxicity	Rare but reported; warn patients about jaundice, dark urine
Suicidal ideation	Black box warning in children and adolescents (similar to antidepressants)
Worsening of psychosis	Caution in patients with psychotic disorders

NON-STIMULANT B: VILOXAZINE

Brand name: Qelbree

Newer selective NE reuptake inhibitor (similar to atomoxetine)
Also has serotonin modulating effects (5-HT2B partial agonist, 5-HT2C antagonist)
FDA approved 2021 for ADHD in children (6-17)
Not a controlled substance
Once-daily dosing

NON-STIMULANT C: GUANFACINE AND CLONIDINE

Brand names: Guanfacine (Intuniv ER), Clonidine (Kapvay ER)

Drug class: Centrally acting α2-adrenoceptor agonists

Mechanism of Action

These drugs mimic NE at POSTSYNAPTIC α2A receptors in the PFC

Normal NE signalling:
Locus coeruleus → releases NE → binds α2A receptors in PFC → strengthens PFC connections → improves attention/working memory

Guanfacine/Clonidine:
Drug directly stimulates α2A receptors → same effect WITHOUT needing NE release

Why do they work even though they also stimulate PRESYNAPTIC α2 receptors (which normally decrease NE release)?

Guanfacine is relatively more selective for postsynaptic α2A receptors
Clonidine is less selective (acts on α2B and α2C too) → more side effects

Clinical Uses

Drug	Use
Guanfacine (Intuniv)	ADHD monotherapy or adjunct; also helps tics/Tourette
Clonidine (Kapvay)	ADHD especially with comorbid tics or sleep disturbance; also used for Tourette, hypertension, opioid withdrawal

Adverse Effects

Adverse Effect	Mechanism	Notes
Sedation	α2 agonism in brainstem	Most common; guanfacine causes less than clonidine
Hypotension	α2 receptors in vasomotor centres → reduce sympathetic tone → lower BP	Do NOT stop abruptly - rebound hypertension
Bradycardia	Reduced sympathetic tone on heart	Monitor pulse
Dry mouth	Reduced salivation
Rebound hypertension on withdrawal	Abrupt cessation → sympathetic surge	Must taper gradually

Note: Clonidine was originally an antihypertensive drug - its use in ADHD exploits its central α2 agonist effects.

COMPLETE ADHD DRUG COMPARISON TABLE

Drug	Class	Mechanism	Schedule	Onset	Duration	Key Side Effect
Methylphenidate	Stimulant	DAT/NET blocker	Schedule II	30-60 min	3-5 h (IR)	Anorexia, insomnia
Dextroamphetamine	Stimulant	DAT/NET blocker + reverser + VMAT inhibitor	Schedule II	30-60 min	4-6 h (IR)	Anorexia, CV effects
Lisdexamfetamine	Stimulant (prodrug)	As above (after hydrolysis)	Schedule II	1-2 h	10-14 h	Less abuse potential
Atomoxetine	NRI	Selective NET blocker	Not controlled	2-6 weeks	Once daily	Suicidal ideation (BBW)
Viloxazine	NRI + 5-HT modulator	NET blocker + serotonin effects	Not controlled	2-4 weeks	Once daily	Somnolence, nausea
Guanfacine	α2A agonist	Postsynaptic α2A receptor agonist	Not controlled	1-2 weeks	Once daily (ER)	Sedation, hypotension
Clonidine	α2 agonist	α2 receptor agonist (less selective)	Not controlled	1-2 weeks	Twice daily (ER)	Sedation, rebound HTN

SECTION 4: ANALOGIES - ADHD

Methylphenidate - "Plugging the Drain"

The synapse is like a swimming pool. Dopamine molecules are the water. The reuptake transporter (DAT) is a large drain at the bottom, sucking water out quickly. In ADHD, the drain is too powerful - the pool empties too fast.

Methylphenidate is like a rubber stopper that plugs the drain. The water (dopamine) stays in the pool longer. The neurons that need dopamine signals get a better, longer signal.

Amphetamine - "Opening the Taps AND Plugging the Drain"

Amphetamine both plugs the drain (blocks reuptake) AND opens the taps (reverses the transporter to release more dopamine from inside the neuron). The pool fills up much faster and stays full longer. This is why amphetamine is more powerful.

Atomoxetine - "The Selective Plumber"

Atomoxetine is more specific than stimulants. Instead of increasing dopamine in the whole brain (which could cause euphoria and addiction), it specifically targets the norepinephrine drain in the prefrontal cortex. It is like a plumber who only works on the pipes in the "executive function room" - not in the "reward room." This is why it has no abuse potential.

Guanfacine - "The Direct Phone Call"

Normally, NE has to travel from the locus coeruleus to the PFC to deliver its message (like a messenger boy). Guanfacine is like a direct phone call to the PFC - it speaks to the α2A receptors directly, without needing NE to be released first. The PFC gets the signal it needs regardless of whether NE supply is adequate.

SECTION 5: CLINICAL REASONING - ADHD

Case: Tommy, 8 years old

Presentation: Tommy's teacher says he cannot sit still, is constantly interrupting, fails to complete tasks, and is falling behind despite being "clearly intelligent." His mother says at home he loses his belongings daily, cannot organise himself, and "is like a tornado." Symptoms have been present since age 5.

Step 1: Is this ADHD?

Symptoms in 2+ settings (school + home) ✓
Onset before age 12 ✓
Causing significant impairment ✓
Combined presentation (inattentive + hyperactive)

Step 2: First-line treatment?

In school-age children (6+): Stimulants are first-line (strongest evidence, fastest onset)

Choice:

Methylphenidate: start low (5 mg immediate release), titrate upward
Dextroamphetamine/Amphetamine: alternative first-line

Step 3: Which formulation?

School-age child:
├── Extended-release (Concerta, Vyvanse): once-daily → avoids school-time dosing embarrassment
└── Immediate-release (Ritalin): twice/three daily → more flexibility but requires school nurse

Parent concerned about abuse/diversion:
└── Lisdexamfetamine (Vyvanse): prodrug → harder to abuse

Step 4: When to use non-stimulants?

Scenario	Drug Choice
Stimulant fails after adequate trial	Atomoxetine or viloxazine
Comorbid tic disorder / Tourette	Guanfacine (also treats tics)
Comorbid anxiety	Atomoxetine preferred (stimulants can worsen anxiety)
Stimulant causing severe insomnia	Add clonidine at bedtime or switch
History of substance abuse	Atomoxetine, viloxazine (not controlled)
ADHD in a toddler (<6 years)	Behavioural therapy ONLY - medications not indicated

Step 5: Long-term management

Regular monitoring of height, weight, heart rate, blood pressure
Annual "drug holiday" assessment (to check if medication is still needed)
Combine with behavioural therapy (combined approach superior to either alone)
Parent and teacher training

SECTION 6: MEMORY TOOLS - ADHD

Mnemonic for Stimulant Adverse Effects: "CAN'T SLEEP"

C - Cardiovascular (increased HR and BP)
A - Anorexia (decreased appetite)
N - Nervousness / Nausea
T - Tics (can worsen)
S - Sleep disturbance (insomnia)
L - Loss of weight
E - Excitability / Emotional lability
E - Elevated growth concerns
A - Abdominal pain
P - Psychosis risk (at high doses)

Mnemonic for Non-Stimulant ADHD drugs: "VAGC"

V - Viloxazine (NRI)
A - Atomoxetine (NRI)
G - Guanfacine (α2A agonist)
C - Clonidine (α2 agonist)

ADHD Neurotransmitter Summary:

DA (Dopamine) ↓ in mesocortical/mesolimbic pathways → motivational and reward problems
NE (Norepinephrine) ↓ in LC → PFC pathway → attentional problems

STIMULANTS → Increase BOTH DA and NE (in PFC and elsewhere)
ATOMOXETINE → Increases NE (and secondarily DA) in PFC only
GUANFACINE → Mimics NE at α2A receptors in PFC directly

SECTION 7: EXAMINER'S CORNER

MANIA - Examiner's Corner

Most Tested Facts:

Lithium mechanism = inositol monophosphatase inhibition + GSK-3 inhibition
Lithium toxicity signs and levels
Drugs that increase lithium levels: NSAIDs, thiazides, ACE inhibitors
Lithium + pregnancy = Ebstein's anomaly
Valproate contraindication in pregnancy = neural tube defects + cognitive harm
Lamotrigine = "depression-minded" mood stabiliser; NOT for acute mania
SJS risk with lamotrigine: go slow, avoid rapid dose escalation, halve dose with valproate
Carbamazepine = aplastic anaemia, autoinduction, CYP3A4 inducer, hyponatraemia
Only mood stabiliser with proven anti-suicide effect = LITHIUM
Mixed episodes and rapid cycling → prefer VALPROATE over lithium

Most Likely Essay Questions:

"Write a note on lithium: mechanism, uses, adverse effects, and toxicity"
"Discuss the pharmacological management of acute mania"
"Compare and contrast lithium and valproate as mood stabilisers"

Most Likely Short Notes:

Lithium toxicity
Mood stabilisers in pregnancy
Anticonvulsants as mood stabilisers

Most Likely Viva Questions:

"What is the therapeutic range of lithium?" (0.6-1.2 mEq/L)
"Why does low sodium diet increase lithium toxicity?"
"Which mood stabiliser is used for bipolar depression?" (Lamotrigine/Quetiapine)
"What is autoinduction? Which drug shows it?" (Carbamazepine)

Most Likely MCQs:

Q: Drug of choice for bipolar depression: Lamotrigine
Q: Drug causing Ebstein's anomaly: Lithium
Q: Most teratogenic mood stabiliser: Valproate
Q: Drug increasing lithium levels: NSAIDs / Thiazides / ACE inhibitors
Q: Mood stabiliser with anti-suicide effect: Lithium
Q: Drug causing aplastic anaemia as a mood stabiliser: Carbamazepine
Q: Lithium toxicity feature at >2.5 mEq/L: Seizures and coma

Common Traps:

❌ "Lamotrigine treats acute mania" - NO, it does NOT
❌ "Carbamazepine and valproate are safe in pregnancy" - NO, both are teratogenic
❌ "Loop diuretics cause lithium toxicity as much as thiazides" - Thiazides are MORE dangerous than loop diuretics
❌ "Lithium failure means the patient cannot be treated" - Try valproate, atypical antipsychotics

ADHD - Examiner's Corner

Most Tested Facts:

Methylphenidate mechanism = blocks DAT and NET (allosteric site)
Amphetamine = blocks + REVERSES DAT/NET + inhibits VMAT
Atomoxetine = selective NET inhibitor; NOT a controlled substance
Lisdexamfetamine = prodrug; lower abuse potential
Guanfacine/Clonidine = α2A receptor agonists
First-line in ADHD: stimulants (methylphenidate or amphetamine)
Atomoxetine: black box warning for suicidal ideation in children
ADHD in <6 years: behavioural therapy only
Stimulants are Schedule II controlled substances
Methylphenidate can INCREASE seizure frequency in epileptics

Most Likely MCQs:

Q: Mechanism of methylphenidate: Blocks DAT and NET
Q: Non-stimulant drug for ADHD: Atomoxetine
Q: Prodrug for ADHD with lowest abuse potential: Lisdexamfetamine
Q: α2A receptor agonist for ADHD: Guanfacine
Q: Black box warning with atomoxetine: Suicidal ideation in children
Q: ADHD drug that is NOT a controlled substance: Atomoxetine / Viloxazine / Guanfacine / Clonidine
Q: Drug for ADHD + comorbid tic disorder: Guanfacine / Clonidine
Q: Adverse effect of stimulants on growth: Growth suppression (via appetite reduction)

Common Traps:

❌ "Methylphenidate works by releasing dopamine" - NO, it BLOCKS reuptake; amphetamine releases
❌ "Stimulants are paradoxically sedating in ADHD" - They are calming via PFC activation but NOT sedating
❌ "Atomoxetine works immediately" - NO, takes 2-6 WEEKS
❌ "Stimulants treat ADHD in adults too" - YES they do; ADHD is a lifelong condition in many

SECTION 9: HIGH-YIELD REVISION SHEETS

MANIA - One-Page Revision Sheet

MUST-KNOW MECHANISMS:

Lithium: Inositol monophosphatase inhibition + G protein modulation + GSK-3 inhibition
Valproate: GABA↑ (GABA transaminase inhibition) + Na⁺ channel blockade
Carbamazepine: Na⁺ channel blockade (inactivated state)
Lamotrigine: Na⁺/Ca²⁺ channel blockade + glutamate release reduction
Antipsychotics: D2 receptor blockade

MUST-KNOW TOXICITIES:

Drug	Lethal/Major Toxicity
Lithium	Seizures/coma (levels >2.5), nephrotoxicity, hypothyroidism, NDI
Valproate	Fatal hepatotoxicity (children <2), pancreatitis, teratogenicity
Carbamazepine	Aplastic anaemia, SJS (esp. HLA-B*1502), hyponatraemia
Lamotrigine	Stevens-Johnson Syndrome

MUST-KNOW CLINICAL USES:

Acute mania: Lithium, Valproate, Antipsychotics
Bipolar depression: Lamotrigine, Quetiapine
Maintenance: All four classic mood stabilisers
Anti-suicide: ONLY Lithium

EXAM EMERGENCY FACTS:

Lithium therapeutic range: 0.6-1.2 mEq/L
Lithium toxicity treatment: IV saline + haemodialysis
Drugs that raise lithium: NSAIDs, Thiazides, ACE-I
Most teratogenic: Valproate
Lamotrigine NOT for acute mania; good for bipolar DEPRESSION
Carbamazepine: autoinduction of own metabolism
Rapid cycling → prefer Valproate
Mixed episodes → prefer Valproate
Anti-suicide mood stabiliser = Lithium
SJS risk with lamotrigine: worse with rapid titration and with valproate co-prescription

ADHD - One-Page Revision Sheet

MUST-KNOW MECHANISMS:

Drug	Mechanism
Methylphenidate	Blocks DAT + NET (allosteric)
Amphetamine	Blocks + reverses DAT/NET; inhibits VMAT
Lisdexamfetamine	Prodrug → dextroamphetamine after hydrolysis
Atomoxetine	Selective NET blocker (no DA reuptake in limbic system → no abuse)
Viloxazine	NET blocker + 5-HT modulation
Guanfacine	α2A postsynaptic agonist in PFC
Clonidine	α2 agonist (less selective than guanfacine)

MUST-KNOW TOXICITIES:

Drug	Key Toxicity
Stimulants	Anorexia, growth suppression, insomnia, CV effects, seizures (in epileptics)
Atomoxetine	Suicidal ideation (BBW), hepatotoxicity, urinary retention
Guanfacine/Clonidine	Sedation, hypotension, rebound hypertension on withdrawal

EXAM EMERGENCY FACTS:

First-line ADHD treatment: Stimulants (methylphenidate or amphetamine)
Non-stimulant, no abuse potential: Atomoxetine / Viloxazine
ADHD + tics: Guanfacine
ADHD + substance abuse: Atomoxetine
Methylphenidate: slow onset? NO - works in minutes to hours
Atomoxetine: slow onset? YES - 2-6 weeks
Lisdexamfetamine = prodrug, lowest abuse potential among stimulants
ADHD in children <6: Behavioural therapy only
Stimulants: Schedule II controlled substances (high abuse potential)
Methylphenidate may INCREASE seizure frequency in epileptics

SECTION 10: SELF-ASSESSMENT

Part A: Mania Self-Assessment (10 Questions)

Q1. A 32-year-old woman with bipolar I disorder has been stable on lithium for 3 years. She presents with drowsiness, coarse tremor, and confusion. Her serum lithium level is 2.3 mEq/L. What is the likely diagnosis, and what is the immediate management?

Answer: Moderate lithium toxicity. Immediate management: (1) Stop lithium immediately. (2) Aggressive IV fluid rehydration with normal saline to increase renal lithium clearance. (3) Monitor levels every 2-4 hours. (4) If level rises above 3.0 mEq/L or neurological symptoms worsen, arrange haemodialysis (most effective way to remove lithium).

Q2. Which enzyme does lithium inhibit to produce the "inositol depletion" effect?

Answer: Inositol monophosphatase (IMPase). By blocking this enzyme, lithium prevents recycling of inositol from inositol monophosphate, depleting the phosphatidylinositol second messenger cycle and reducing overactive neuronal signalling.

Q3. A patient on lithium is prescribed ibuprofen for back pain. What do you advise?

Answer: Avoid NSAIDs with lithium. NSAIDs reduce renal prostaglandin synthesis, which decreases renal blood flow and glomerular filtration. This reduces lithium excretion, causing lithium levels to rise and increasing the risk of toxicity. Advise paracetamol (acetaminophen) as a safer analgesic alternative.

Q4. What is the first-line treatment for bipolar depression?

Answer: Lamotrigine (especially for maintenance/prevention of depressive episodes, particularly in bipolar II) and Quetiapine (for acute bipolar depression). Note that lithium and lamotrigine together are a common combination for bipolar depression. Antidepressant monotherapy is generally avoided in bipolar disorder as it can trigger mania or rapid cycling.

Q5. A 25-year-old woman with bipolar disorder is planning a pregnancy. You are reviewing her current medication (sodium valproate). What action do you take and why?

Answer: Valproate must be stopped or switched before conception. Reasons: (1) It causes neural tube defects (spina bifida, anencephaly) in 2-5% of exposed fetuses. (2) It causes valproate syndrome (craniofacial defects, limb abnormalities). (3) Most critically, it causes irreversible neurodevelopmental harm (reduced IQ by 8-10 points, autism spectrum disorder, ADHD, cognitive delays) in children exposed in utero. Switch to a safer alternative such as lamotrigine or quetiapine, with folic acid supplementation.

Q6. What is autoinduction, and which mood stabiliser demonstrates it?

Answer: Autoinduction is when a drug induces its own metabolism by upregulating the CYP enzymes (especially CYP3A4) responsible for its own breakdown. Carbamazepine demonstrates autoinduction. When started, its initial plasma level may be adequate. Over 2-4 weeks, it induces CYP3A4 (and other CYPs), metabolising itself faster. This leads to falling carbamazepine levels despite the same dose, requiring dose increases to maintain efficacy.

Q7. Which HLA allele increases the risk of Stevens-Johnson Syndrome with carbamazepine, and in which population is this common?

Answer: HLA-B*1502 allele, found predominantly in Han Chinese and other Southeast Asian populations (including Thai, Malaysian, Filipino, Indian to a lesser degree). Genetic testing for this allele before starting carbamazepine is recommended in these populations. If positive, carbamazepine should be avoided.

Q8. List four features of moderate lithium toxicity (serum level 2.0-2.5 mEq/L).

Answer: (1) Confusion/disorientation, (2) Coarse tremor (more prominent than the fine tremor of therapeutic levels), (3) Ataxia (unsteady gait, poor coordination), (4) Dysarthria (slurred speech). Additional features include muscle twitching (fasciculations), agitation, and hyperreflexia.

Q9. A patient with bipolar disorder has had 5 manic episodes in the past year. Which mood stabiliser is preferred and why?

Answer: Valproate is preferred over lithium for rapid cycling bipolar disorder (defined as 4+ mood episodes per year). Valproate has demonstrated superiority over lithium in rapid cycling patients. Additionally, if there are mixed features (mania + depressive symptoms co-occurring), valproate is again preferred.

Q10. What is unique about lithium compared to all other mood stabilisers regarding suicide?

Answer: Lithium is the only mood stabiliser with proven anti-suicide effects. Multiple long-term studies have shown that lithium significantly reduces completed suicides, suicide attempts, and self-harm in patients with mood disorders. The mechanism likely involves its effects on serotonin (increasing serotonergic activity), its neuroprotective effects via GSK-3 inhibition, and reduction in impulsivity. This unique property is an important reason to continue lithium despite its side effect burden and monitoring requirements.

Part B: ADHD Self-Assessment (10 Questions)

Q1. Explain the paradox: Why do stimulants CALM a hyperactive child?

Answer: In ADHD, the prefrontal cortex (PFC) - the brain's "executive control centre" - is underactive due to insufficient dopamine and norepinephrine. The PFC is responsible for inhibiting hyperactive behaviour, controlling impulses, and sustaining attention. Stimulants increase DA and NE in the PFC, activating these control circuits. When the PFC works properly, it exerts inhibitory control over the limbic system and motor systems, reducing hyperactivity and impulsivity. The net result is behavioural calming, not chemical sedation.

Q2. How does methylphenidate differ mechanistically from amphetamine?

Answer: Methylphenidate binds to the DAT/NET at an allosteric site (not the DA-binding site) and physically blocks the transporter, preventing reuptake. It does NOT enter the neuron. Amphetamine acts as a competitive substrate at DAT/NET and actually enters the neuron as a "hitch-hiker." Inside the neuron, it inhibits VMAT (vesicular monoamine transporter), causing DA to leak out of vesicles into the cytoplasm. It then reverses the direction of DAT (reverse transport), flooding the synapse with DA. Amphetamine therefore both blocks reuptake AND forces release of DA, making it more potent.

Q3. Why does atomoxetine have no abuse potential despite increasing dopamine in the PFC?

Answer: Abuse potential is driven by rapid, large increases in dopamine in the limbic system (nucleus accumbens, mesolimbic pathway). Atomoxetine selectively blocks the NET (norepinephrine transporter). In the limbic system, dopamine clearance is handled by DAT (not NET) - so atomoxetine does NOT increase DA in the limbic reward circuit. In the PFC however, the NET is responsible for clearing both NE and DA (PFC has low DAT expression). So atomoxetine increases NE and DA in the PFC (therapeutic effect) but NOT in the limbic system (no reward/euphoria/abuse).

Q4. A 12-year-old with ADHD and Tourette syndrome needs pharmacotherapy. What is your drug of choice?

Answer: Guanfacine (Intuniv). Guanfacine is a selective α2A receptor agonist that improves ADHD symptoms via PFC strengthening AND has documented efficacy in reducing tic frequency and severity in Tourette syndrome. Stimulants are relatively contraindicated in Tourette (they can worsen tics by increasing dopamine). Atomoxetine is also an acceptable option. Clonidine can also be used but causes more sedation.

Q5. What is lisdexamfetamine? Why was it designed as a prodrug?

Answer: Lisdexamfetamine (Vyvanse) is a prodrug consisting of L-lysine chemically bonded to dextroamphetamine. After oral ingestion, gut/blood enzymes cleave the lysine, releasing dextroamphetamine. The prodrug design serves two purposes: (1) Lower abuse potential - it cannot be administered intranasally or intravenously (the prodrug form is inactive; conversion requires enzymatic hydrolysis that only occurs orally/systemically). This makes diversion and misuse less attractive. (2) Smoother, longer duration - the conversion step slows down the rise in dextroamphetamine levels, reducing the "rush" and prolonging the therapeutic effect (10-14 hours).

Q6. A 16-year-old boy with ADHD on methylphenidate develops increased seizure frequency. How do you manage this?

Answer: Methylphenidate can lower the seizure threshold in patients with epilepsy. The appropriate management is: (1) Discuss the risk-benefit with patient and family. (2) Optimise anticonvulsant therapy first. (3) Consider switching ADHD medication to a non-stimulant - atomoxetine has the best evidence for use in ADHD with epilepsy (it does not lower seizure threshold). (4) If stimulant treatment is essential, use the lowest effective dose with close monitoring. Guanfacine is another non-stimulant option.

Q7. What is the black box warning on atomoxetine? What is the pharmacological basis?

Answer: Atomoxetine carries a black box warning for suicidal ideation in children and adolescents (similar to antidepressants). The pharmacological basis: atomoxetine is structurally and mechanistically similar to selective serotonin/norepinephrine reuptake inhibitors (SNRIs). Increased norepinephrine (and possibly serotonin-related effects) in the developing brain during initial treatment may trigger suicidal thinking in vulnerable individuals. This does not mean it causes suicide, but patients must be monitored closely, especially in the first weeks of treatment, for worsening mood, agitation, or suicidal thoughts.

Q8. Why should guanfacine and clonidine NEVER be stopped abruptly?

Answer: Both guanfacine and clonidine are α2 adrenoceptor agonists that work by reducing sympathetic nervous system activity (sympatholytic effect). With chronic use, the body compensates by upregulating α1 and β adrenoceptors on blood vessels and the heart. If the drug is suddenly stopped, sympathetic activity rebounds strongly, acting on these upregulated receptors → rebound hypertension (sometimes severe and dangerous), tachycardia, and agitation. This is called sympathetic rebound. Both drugs must be tapered gradually over 1-2 weeks when discontinuing.

Q9. Compare the onset of action: stimulants vs atomoxetine.

Answer: Stimulants (methylphenidate, amphetamine): Onset within 30-60 minutes after oral administration. Peak effect in 1-2 hours. Effects are immediately noticeable. This is because they rapidly increase DA and NE in the synapse. Atomoxetine: Onset is delayed by 2-6 weeks. Initial doses have measurable pharmacological effects but clinically meaningful improvement in ADHD symptoms takes weeks. This is because atomoxetine requires sustained NE receptor upregulation and synaptic remodelling in the PFC for full clinical effect - similar to antidepressant lag time.

Q10. List three reasons to prefer a non-stimulant over a stimulant in ADHD.

Answer:

Substance abuse history - Stimulants are Schedule II controlled substances with high abuse and diversion potential; atomoxetine or viloxazine has no abuse potential
Comorbid tic disorder/Tourette syndrome - Stimulants worsen tics; guanfacine/clonidine improve tics and ADHD simultaneously
Comorbid anxiety disorder - Stimulants can increase anxiety, heart rate, and agitation; atomoxetine or guanfacine are better tolerated in anxious patients Additional valid answers: history of cardiac disease (stimulants increase HR/BP), severe insomnia not controlled with dose adjustment, need for once-daily coverage without abuse risk, patient preference

Sources consulted: Stahl's Essential Psychopharmacology (Neuroscientific Basis, 5e) - Stahl SM; Lippincott Illustrated Reviews: Pharmacology (7e); Kaplan & Sadock's Comprehensive Textbook of Psychiatry (10e); Katzung's Basic and Clinical Pharmacology (16e); Eric Kandel's Principles of Neural Science (6e)

Recent evidence note: A 2025 network meta-analysis (PMID: 39128561) confirmed antipsychotics and mood stabilisers remain comparably effective in paediatric acute mania. A 2026 Lancet Psychiatry dose-effect network meta-analysis (PMID: 42134365) found all approved ADHD pharmacotherapies effective, with dose-dependent response confirming the importance of careful titration. A 2025 JAMA Network Open meta-analysis (PMID: 40343695) confirmed stimulant safety across populations when appropriately screened.

This is a shared conversation. Sign in to Orris to start your own chat.